Acquista crypto Mercati Spot FuturesGOLD Earn Centro eventi

Altro

COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ — Curasight A/S (“Curasight” or “the Company” – (CPH: CURAS) a clinical-stage theranostic company focused on diagnosingCOPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ — Curasight A/S (“Curasight” or “the Company” – (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing

Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Autore: AI Journal

Fonte: AI Journal

2026/01/05 18:15

2 min di lettura

CPH$0.004801+4.14%

Per feedback o dubbi su questo contenuto, contattateci all'indirizzo crypto.news@mexc.com.

COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ — Curasight A/S (“Curasight” or “the Company” – (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain types of cancers, announced that CEO Ulrich Krasilnikoff and CMO prof. Andreas Kjær will be in San Francisco during the 44^th J.P. Morgan Healthcare Conference being held January 12-15, 2026.

During the week, Curasight management will hold meetings with investors and other industry stakeholders. The meetings will include updates on the Company’s clinical progress, including the recent initiation of a Phase 1 trial with uTREAT® in aggressive brain cancer, and the ongoing Phase 2 trial of uTRACE® in prostate cancer conducted in partnership with Curium Inc.

About the uPAR theranostic platform

Curasight’s uPAR theranostic platform combines two key technologies – uTRACE and uTREAT both targeting the uPAR receptor. uTRACE is designed to deliver sensitive imaging for diagnosis, while uTREAT offers a targeted radiopharmaceutical solution. Together, they form an integrated approach to improving the diagnosis and treatment of cancers that express uPAR. Curasight’s ambition is to develop both uTRACE and uTREAT to improve diagnosis and treatment of uPAR-expressing cancers.

For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com

www.curasight.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/curasight/r/curasight-to-hold-meetings-in-san-francisco-during-j-p–morgan-healthcare-conference-week,c4288616

The following files are available for download:

https://mb.cision.com/Main/19744/4288616/3862590.pdf

Curasight Press release – JPM 26

View original content:https://www.prnewswire.com/news-releases/curasight-to-hold-meetings-in-san-francisco-during-jp-morgan-healthcare-conference-week-302652512.html

SOURCE Curasight

Opportunità di mercato

Valore Cypherium (CPH)

$0.004801

$0.004801$0.004801

+1.18%

USD

Grafico dei prezzi in tempo reale di Cypherium (CPH)

Get 20 USDT in Just 1 Minute

Deposit $100 to unlock $300 in GOLD positions

Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta crypto.news@mexc.com per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.